Notch pathway inhibition with crenigacestat (LY3039478) in a phase I first-in-human clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia

Notch pathway inhibition with crenigacestat (LY3039478) in a phase I first-in-human clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia

Background: Deregulated Notch signaling is implicated in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Crenigacestat (LY3039478) prevents cleavage of Notch proteins and may benefit patients with relapsed or refractory NHL or CLL. Objectives: This phase I clinical trial assessed...

Full description

Saved in:
Bibliographic Details
Main Authors: Jean-Marie Michot, Zsofia Balogh, Jennifer R. Brown, Vincent Ribrag, Antoine Hollebecque, Rastislav Bahleda, Cyril Quivoron, Samy Ammari, Jean-Yves Scoazec, Karim A. Benhadji, Christophe Massard
Format: Article
Language:English
Published: SAGE Publishing 2025-07-01
Series:Therapeutic Advances in Drug Safety
Online Access:https://doi.org/10.1177/20420986241311461
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1177/20420986241311461

Similar Items